- Conditions
- Leukemia
- Interventions
- sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT
- Biological · Drug · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2019
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 69 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 1,869
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mechanical Ventilation, Sedation and Analgesia, Critical Care, Intensive Care
- Interventions
- fentanyl, Hydromorphone
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia
- Interventions
- Placebo, RO5545965
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • St Louis, Missouri
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Nivolumab, Etoposide, Prednisolone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine, Placebo, Rebif® new formulation (RNF)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
- Conditions
- Childhood Obesity, Evidence-Based Practice, Food Systems, Food Policy
- Interventions
- Catalyzing Communities, FICAS Implementation Intervention
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hepatitis C, Hepatocellular Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Target PharmaSolutions, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 37 more
- Conditions
- Refractory Infantile Spasms
- Interventions
- JBPOS0101
- Drug
- Lead sponsor
- Bio-Pharm Solutions Co., Ltd.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Complex Regional Pain Syndrome Type I, Complex Regional Pain Syndrome Type II
- Interventions
- Placebo, Neurotropin
- Drug
- Lead sponsor
- National Institute of Nursing Research (NINR)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Cancer
- Interventions
- CLR 131
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Johnson Creek, Wisconsin • Madison, Wisconsin
- Conditions
- Orthopoxviral Disease, Smallpox, Monkey Pox
- Interventions
- ST-246 Days 1 - 3, ST-246 Days 11 - 13
- Drug
- Lead sponsor
- SIGA Technologies
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Advanced Basal Cell Carcinoma
- Interventions
- Vismodegib 150 MG Oral Capsule
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Solid Tumor
- Interventions
- IMP1734
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 18 more
- Conditions
- Nicotine Dependence
- Interventions
- Varenicline, Initial Individual counseling, Check-ins with medical staff, Extended Individual Counseling - Health Model, Extended Individual Counseling - Relapse Prevention Model
- Drug · Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Locally Advanced Head and Neck Cancer
- Interventions
- Xtampza ER
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Biological · Procedure
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 28
- States / cities
- Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferumoxytol, Oral Iron
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Posterior Blepharoconjunctivitis
- Interventions
- Azithromycin ophthalmic solution, 1%
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Biophoton Generators
- Device
- Lead sponsor
- First Institute of All Medicines
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Butler, Pennsylvania
- Conditions
- Parkinson Disease, Healthy Participants
- Interventions
- TAK-071, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 21
- States / cities
- Garden Grove, California • Irvine, California • Los Angeles, California + 18 more
- Conditions
- Parkinson Disease
- Interventions
- Nordic walking exercise
- Other
- Lead sponsor
- Grand Valley State University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Asthma
- Interventions
- E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg
- Drug
- Lead sponsor
- Amphastar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- San Jose, California • Stockton, California